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This review is focused on discussing in some detail possible neuroprotective functions of
microglial cells. We strive to explain how loss of these essential microglial functions might
contribute toward the development of characteristic neuropathological features that char-
acterize Alzheimer’s disease. The conceptual framework guiding our thinking is provided
by the hypothesis that microglial senescence accounts for impaired neuronal protection
and consequent neurodegeneration.
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INTRODUCTION
The role of CNS microglial cells in the development of Alzheimer’s
disease(AD) has been the subject of considerable interest since
McGeer’s initial description of reactive microglia in human AD
brain in 1987 (McGeer et al., 1987). Most of the numerous
studies that followed corroborated McGeer’s findings and col-
lectively over the years they coalesced into the amyloid cascade-
neuroinflammation hypothesis, which claims that neurodegener-
ative changes in AD (neurofibrillary degeneration) are the result
of an uncontrolled, chronic intracerebral inflammatory reaction
triggered by the accumulation/aggregation of amyloid-beta (Aβ)
protein in plaques. Today, the neuroinflammation hypothesis is
difficult to uphold given that clinical trials with anti-inflammatory
drugs and strategies to remove Aβ from the brain have met with
disappointing results and have yielded little in the way of effec-
tive treatments for humans. In this paper, we briefly describe our
own vision of what may be the role of microglia in AD patho-
genesis, which is different in that our primary focus is not on a
single protein (Aβ) as the cause of AD, but instead relies on the
incontrovertible fact that the incidence of sporadic AD is strongly
correlated with aging. Our theory, which we call the microglial
dysfunction hypothesis, states that neurodegeneration in AD is
the result of an aging-related, gradually progressive breakdown of
innate CNS immunity and loss of neuroprotection, i.e., microglial
cell senescence. In contrast to normal aging this deterioration of
innate CNS immunity appears to be accelerated in AD. The dif-
ference in perspective between the dysfunction hypothesis and
the neuroinflammation theory is due in large part to our convic-
tion that microglia are entirely beneficial cells, whose single-most
important function is to provide neuronal protection at all times
in the normal and injured CNS. In the following, we shall discuss
succinctly several microglial neuroprotective functions and how
senescent deterioration of these could contribute to development
of neurodegenerative changes.
THE BRAIN’S INNATE IMMUNE SYSTEM IS
NEUROPROTECTIVE
Even though doubts about the very existence of microglia were
expressed in textbooks until the early 1990s (Graeber, 2010), the
notion that microglia are the key cellular elements comprising the
brain’s innate immune system (Graeber and Streit, 1990; Streit
and Kincaid-Colton, 1995) is now widely recognized. A common
view that has been expressed many times is that together with
peripheral macrophages, such as Kupffer cells of the liver, Langer-
hans cells of the epidermis, or alveolar macrophages in the lung,
microglia are another member of the mononuclear phagocyte sys-
tem, i.e., a tissue-specific macrophage. While there is little doubt
regarding validity of a mononuclear lineage relationship, microglia
in the CNS do not maintain a macrophage state constitutively or
continuously. In the normal adult brain, microglia display a well-
differentiated, dendritic morphology similar to that of other brain
cells. They exhibit multiple, finely branched cytoplasmic processes
with which they constantly explore the CNS microenvironment
searching for disturbances that may require their quick response
(Nimmerjahn et al., 2005; Tremblay et al., 2010). These ramified
microglia are sensors of pathology (Kreutzberg, 1996; Stence et al.,
2001; Petersen and Dailey, 2004; Davalos et al., 2005) and they do
not exhibit macrophage morphology, nor do they express the typ-
ical macrophage marker, CD68 (recognized by ED1 antibody in
the rat). Even activated microglia with hypertrophic morphology
express the CD68 antigen only after having engaged in phago-
cytic activity (Graeber et al., 1998). It is therefore only under
conditions of tissue/cell necrosis when debris must be phagocy-
tized that microglia show expression of CD68 and can therefore
be considered brain macrophages. The currently popular idea of
differentiating functionally distinct macrophage phenotypes clas-
sified as M1 (cytotoxic), M2 (reparative), and a third,“deactivated”
form might thus apply merely to those few microglial cells that at
any given time are in a macrophage state during CNS injury or
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disease. To generalize and assume that the M1/M2 classification
applies to the microglial population at large represents a rather
indiscriminate extrapolation of in vitro studies performed with
peripheral macrophages (Colton, 2009; Michelucci et al., 2009;
Moon et al., 2011), and it could be misleading to assume that
resting and activated microglia within the brain microenviron-
ment function in the same manner as peripheral (professional)
macrophages that have been cultured and manipulated in vitro
with cytokines. There is currently no way of reliably identifying
functionally distinct microglial phenotypes in brain tissue in situ
and without this capability no real progress on functional involve-
ment of putative M1 or M2 microglial subtypes in the cellular
pathogenesis of AD can be made. In part because of this we are
assuming that all microglia are potentially beneficial cells and our
view of microglial involvement in AD is rooted firmly in that
assumption. It is known that the CNS parenchyma represents a
unique compartment that is segregated to a large extent from the
rest of the body by the blood brain barrier (BBB), and that it
represents an immunologically subdued environment (Ford et al.,
1995; Perry et al., 1995; Carson et al., 1998; Hoek et al., 2000; Car-
dona et al., 2006), although not necessarily an “immunologically
privileged site” (Galea et al., 2007). There are no constitutively
active (professional) macrophages in the brain parenchyma under
normal conditions. Our definition of a microglial cell is that of
a cell type of the mononuclear cell lineage that has evolved to
be highly adapted and specialized for residing within the unique
CNS microenvironment. As such its immunological potential is
limited largely to phagocytosis while its neuroprotective capabili-
ties are maximized, and one might thus view microglia as a hybrid
between a moderately immunocompetent mononuclear cell and a
powerful neuroprotective glial cell.
We view the neuroprotective capabilities of microglia in the
broadest possible meaning of the term, namely, anything that
microglia do that is beneficial for and/or conducive toward
proper neuronal functioning. One obvious beneficial function of
microglia is simply their ability to transform into macrophages
that can clear out debris and process waste when/if the need arises.
These microglia-derived macrophages are not necessarily cyto-
toxic because much of the debris generated within the brain, for
example after trauma or is chemia, is sterile (Chen and Nunez,
2010) and would thus not require elaboration of cytotoxins to kill
microorganisms. Direct infection of the CNS with microorgan-
isms is largely prevented by the natural barriers of skull, meninges,
and BBB, but if these fail and when microorganisms do gain
access to the parenchyma, they are likely to be eliminated quickly
and efficiently by microglial cells and probably without too much
collateral damage, as there are multiple mechanisms involved in
post-infection neuropathology other than microglial neurotox-
icity (Nau and Bruck, 2002; Mariani and Kielian, 2009; Ribes
et al., 2011). One condition that deserves special mention is infec-
tion with the human immunodeficiency virus-1 (HIV-1), where
microglial cells themselves are the target of the infectious agent
(Michaels et al., 1988). It is therefore reasonable to assume that the
functionality of HIV-infected microglia is compromised, although
in ways that are not yet entirely understood. From our perspective,
compromised microglial function includes primarily an impaired
ability to provide neuroprotection, and it is perhaps because of
FIGURE 1 | Lectin staining of microglia (brown) in the normal cerebral
cortex of a rabbit shows two microglial cells (arrows) extending their
processes around cortical neurons. This close spatial relationship
suggests ongoing interactions between resting microglia and neurons.
Neurons are stained with cresyl violet. Scale bar: 50µm.
this that patients with HIV/AIDS frequently suffer from the con-
sequences of neurodegeneration, a.k.a. HIV-associated dementia
(Anthony and Bell, 2008). It seems obvious that compromised
innate immunity within the CNS due to HIV infection is what
accounts at least in part for the high incidence of opportunis-
tic CNS infections in HIV/AIDS patients, notably toxoplasmosis
(Mariani and Kielian, 2009).
A second and very direct neuroprotective function provided by
microglia is the production and secretion of neurotrophic factors,
notably BDNF (Elkabes et al., 1996; Batchelor et al., 1999; Suzuki
et al., 2001; Nakajima et al., 2002; Coull et al., 2005) and NGF (Mal-
lat et al., 1989; Heese et al., 1997; Frade and Barde, 1998), but also
others like TGF-β (Kiefer et al., 1993; Lehrmann et al., 1998), bFGF
(Araujo and Cotman, 1992), and GDNF (Batchelor et al., 1999;
Suzuki et al., 2001). Production of neurotrophins by microglia
is usually increased after injury/during recovery when the cells
become activated and neurons require more neurotrophic support
than under normal conditions. However, even under normal con-
ditions microglia are likely to sustain neuronal functioning during
periods of high activity or sub-pathological stress when smaller
doses of neurotrophic factors may be required. Although it is dif-
ficult to demonstrate directly that this type of specific microglial-
neuronal interaction actually occurs, histological images showing
some neurons covered tightly by microglial processes suggests that
this could be the case (Figure 1). Different neuronal populations
require different neurotrophic factors and quite possibly microglia
have the ability to sense which factors and how much of them may
be needed in any particular circumstance. Their ability to migrate
and home in on neurons in need is essential for facilitating such
targeted neuroprotection.
A third way in which microglia can be neuroprotective is
by diverting noxious and potentially harmful substances away
from neurons. It has long been known that astrocytes take
up excess glutamate from the extracellular space under condi-
tions of heightened neuronal activity in an effort to minimize
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glutamate-mediated excitotoxicity. During the past 10 years it has
become clear that astrocytes are not alone in this effort and that
activated microglial cells also participate in the removal of glu-
tamate by upregulating primarily glutamate transporter-1 (GLT-
1) in vivo following traumatic lesions as well as in vitro after
stimulation with LPS, TNF-α, or neuronal conditioned medium
(Lopez-Redondo et al., 2000; Nakajima et al., 2001, 2008; van Lan-
deghem et al., 2001). Interestingly, glutamate uptake by microglia
is coupled to enhanced glutathione synthesis by microglia, per-
haps reflecting an effort by the cells to protect themselves from
damage (Persson et al., 2006). These studies underscore the exten-
sive crosstalk that takes place continuously between microglia and
neurons. In addition to glutamate, a second substance with con-
siderable and non-specific damage potential is free, redox-active
iron, which may be present either as ferric (Fe+3) or ferrous (Fe+2)
ions. We propose that the sequestration of free iron in the CNS
by ferritin in microglia constitutes an important neuroprotective
mechanism that becomes most relevant when there is a breach in
the BBB and the possibility exists of free iron entering the brain
parenchyma. The evidence for this mechanism of microglial neu-
roprotection is as follows: we and others have previously reported
that many of the dystrophic (senescent) microglia in human brain
are positive for the iron storage protein, ferritin (Simmons et al.,
2007; Lopes et al., 2008), suggesting that the sequestration and
concomitant accidental escape of free iron atoms can contribute
to microglial senescence by increasing oxidative stress within these
cells. This has raised the interesting and novel possibility that
microglia rather than neurons may be primary victims of oxida-
tive damage (Dringen, 2005; Lopes et al., 2008; Nakanishi and Wu,
2009), representing somewhat of a paradigm shift since in the past
microglia have been seen primarily as a source of free radicals that
endanger neuronal survival (Colton and Gilbert, 1987; Boje and
Arora, 1992; Chao et al., 1992). It seems plausible then to think that
microglia can protect neurons by taking the brunt of at least some
oxidative stress and deflecting it away, which makes sense since
microglia are relatively expendable and possess renewal capac-
ity from within the CNS (mitosis) or from bone-marrow derived
precursor cells. One might draw the analogy to the game of chess
where pawns are sacrificed to save the more valuable pieces. Com-
patible with this idea of microglial self-sacrifice is evidence from
animal experiments showing that activated microglia in the axo-
tomized facial nucleus are negative for ferritin (unpublished) and
that therefore ferritin expression in microglia is not necessarily
linked to microglial activation. Importantly, transection of the
facial nerve leaves the BBB undisturbed, but conversely, when a
brain lesion does result in a breach of the BBB some microglia do
become ferritin-positive and even dystrophic (Xue et al., 2010).
Thus, neuroprotective microglia are like the HazMat Team in the
CNS which will put itself in harm’s way to protect neurons.
A final aspect of microglial neuroprotection within the scope
of this discussion concerns their emerging role in the regulation of
the plasticity of neuronal circuits, that is, their involvement in the
pruning/elimination and maintenance of synaptic connections.
This aspect of the microglial functional repertoire was recog-
nized for the first time more than 40 years ago by Blinzinger and
Kreutzberg (1968), yet it remained largely unexplored until quite
recently when a number of laboratories started to reexamine and
delve deeper into this phenomenon. It now appears that microglial
regulation of neuronal connectivity is important during develop-
ment, as well as in the normal and injured adult brain (Wake
et al., 2009; Tremblay et al., 2010; Paolicelli et al., 2011). The strip-
ping of synapses from axotomized motoneurons (Blinzinger and
Kreutzberg, 1968) perhaps best illustrates a direct neuroprotective
effect of such cellular action in that displacement of synapses from
the surface of injured motoneurons may prevent afferent excita-
tion, which is hardly needed at a time when motoneurons are
working to regenerate their severed axons (Streit, 1993). In fact,
tight microglial ensheathment of injured motoneurons instanta-
neously fulfills multiple goals of neuroprotection: while preventing
unnecessary excitation through synaptic displacement, it also puts
microglia into very close proximity to the neuronal cell soma to
facilitate targeted delivery of neurotrophic factors and, in addition,
it perfectly prepositions microglia for rapid phagocytosis should
a neuron fail to survive as a result of having been axotomized.
Elimination of synapses during development (Paolicelli et al.,
2011) or during altered sensory processing (Tremblay et al., 2010)
is neuroprotective insofar as it facilitates the proper formation
and rearrangement of synaptic connections and thus optimizes
neuronal functioning.
NEUROINFLAMMATION AND THE SIGNIFICANCE OF
MICROGLIAL ACTIVATION IN AD
Countless studies in laboratory animals involving experimental
CNS lesions have shown that microglia become activated rapidly
in response to neuronal injury (Kreutzberg, 1996; Kettenmann
et al., 2011). This prompt cellular reaction to CNS tissue injury
(glial activation), which can occur within seconds after injury
(Nimmerjahn et al., 2005), constitutes acute neuroinflammation.
The primary purpose of such acute inflammation, being limited
in its range to the immediate vicinity of the lesion, is to initiate
wound healing and to restore homeostasis as soon as possible, and
microglial activation subsides as healing occurs. Excess microglia
generated during the activation response via mitosis of resident
cells undergo programmed cell death which reduces cell num-
bers back to baseline (Gehrmann and Banati, 1995; Jones et al.,
1997; Conde and Streit, 2006), constituting a form of physiological
cell death perhaps similar to what happens in normal ontoge-
netic development. One seemingly trivial insight to be gained
from these lesion studies is that they clearly establish the cause-
and-effect relationship between injury and subsequent microglial
activation underscoring the fundamental definition of inflamma-
tion, i.e., the cellular response to injury. In the context of AD
and the amyloid cascade-neuroinflammation theory a cause-and-
effect relationship is anything but trivial. Although deposition of
the Aβ protein is seen by many as a trigger for microglial activation
in AD and has thus given rise to a large body of literature result-
ing from sundry experimental approaches, there is no consensus
to date whether or not Aβ actually stimulates microglial activa-
tion. Case in point, we and others have observed that some human
brains with substantial Aβ loads reveal a notable lack of microglial
activation (Itagaki et al., 1989; Ohgami et al., 1991; Streit et al.,
2009; Figure 2). Similarly, the supposition that microglial cells
are involved in the clearance of Aβ has not been proven. Gener-
ally speaking, studies performed in vitro with cultured microglia
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FIGURE 2 | Double immunofluorescent staining for microglia (Iba1)
and Aβ protein (10D5) in the cerebral cortex of a human with Down
syndrome reveals apparently normal, non-activated microglia in and
around Aβ deposits. Microglia are ramified and show no evidence of
having internalized any Aβ protein. Two microglial cells show presence of
intracellular, autofluorescent lipofuscin (arrows). Scale bar: 50µm.
provide the only convincing evidence that microglia can phagocy-
tize Aβ protein, but these stand in stark contrast to most studies
in Aβ-overexpressing animal models (which do not) and certainly
to studies in human brain which reveal a lack of Aβ phagocy-
tosis by microglia. Thus, the relationship between Aβ, microglial
activation, and/or neuroinflammation remains enigmatic and per-
plexing even after more than 20 years of intense research. If one
also considers the alleged causal connection between amyloid
deposits and neurofibrillary degeneration the picture gets blurred
even more as this connection seems to grow weaker and evidence
is mounting against rather than in favor of it.
Yet another issue that complicates our understanding of neu-
roinflammation in AD is found in the fact that primary infections
outside of the CNS influence the state of microglial cells. In partic-
ular, sepsis, which is more commonly found in elderly patients due
to compromised immune function, will induce microglial activa-
tion within the brain (Lemstra et al., 2007; Streit et al., 2009).
It is likely that there are other types of systemic pathology that
may do so as well (Mattiace et al., 1990). Nearly all prior studies
that have reported microglial activation and/or upregulation of
inflammatory cytokines in the CNS of AD subjects have not made
a distinction between cases that were free of peripheral infectious
disease and those that were not, and it is therefore quite possi-
ble that neuroinflammatory changes reported could have been
the result of peripheral diseases. Studies are underway in our
laboratory to further investigate this possibility.
MICROGLIAL SENESCENCE AND
NEURODEGENERATION – CONNECTING THE DOTS
The discovery of dystrophic microglia in human brain represents
a critical step in conceiving the microglial dysfunction hypoth-
esis because it raises the possibility that microglia are subject
to senescence and degeneration (Streit et al., 2004). Dystrophic
microglia were first identified in the aged human brain as cells
displaying abnormal morphological features, such as shortened,
gnarled, beaded, or fragmented cytoplasmic processes, as well as
loss of fine ramifications and formation of spheroidal swellings.
Because they are present in greater numbers in aged vs. young
humans microglial dystrophy is thought to reflect degenerative
changes related to cell senescence. Our subsequent demonstration
of a close spatial and temporal relationship between neurofibrillary
degeneration (tau pathology) and microglial dystrophy in subjects
with either AD or Down syndrome has provided another crucial
piece in the puzzle consolidating the dysfunction theory by linking
microglial senescence and neurodegeneration (Streit et al., 2009;
Xue and Streit, 2011). Additional support for this link is derived
also from the well-known fact that aged rodents typically do not
develop neurofibrillary degeneration, and that microglial degener-
ation has been undetectable in uninjured rodent brain (Streit and
Xue, 2010). Clearly, the next major step in advancing this line of
thinking would be to induce microglial dystrophy experimentally
and determine if it is accompanied by neurodegenerative changes.
Current efforts in our laboratory are directed toward that goal.
The morphological abnormalities that characterize dystrophic
microglia have been described in detail before (Streit et al., 2004,
2009; Xue and Streit, 2011), suffice it to say here that the most
advanced and striking change involves fragmentation of the cells’
cytoplasm, which is termed cytorrhexis (Figure 3). Cytorrhexis
reflects obvious degeneration of cell structure and it appears to be
the end result of a progression from beading of processes to sub-
sequent fragmentation not unlike what has been observed during
axonal degeneration (Kerschensteiner et al., 2005; Coleman and
Freeman, 2010). We view microglial cytorrhexis as a form of acci-
dental cell death with as of yet unknown causes, although much
points toward undue oxidative stress as a likely etiologic factor. Our
prior work has shown that cytorrhexis does not involve detectable
nuclear fragmentation further supporting the idea of an accidental
rather than an apoptotic mechanism (Fendrick et al., 2007).
With regard to the aforementioned neuroprotective roles of
microglia, there are a number of interesting points to consider
in terms of how deterioration of these neuroprotective functions
could be critically important in the development of aging-related
neurodegenerative diseases. Phagocytosis of debris by microglia is
an essential cellular activity that ensures maintenance of a clean,
debris-free brain parenchyma, and is conducive toward facilitat-
ing optimal interneuronal electrochemical signaling. A substantial
decline in microglial phagocytosis due to cell senescence and/or
degeneration would almost certainly contribute to NDD develop-
ment (Neumann et al., 2009). In addition, impaired phagocytosis
could be a factor contributing to reduced clearance of amyloid
deposits, a possibility that has been raised in previous reports
(Fiala et al., 2005; Streit et al., 2008; Njie et al., 2012). Areas of the
human brain showing advanced tau pathology are characterized
by widespread presence of cytorrhectic microglia but also reveal a
conspicuous absence of phagocytic activity. This very likely reflects
the fact that fragmented microglia cells no longer are capable of
performing phagocytosis, which explains why areas of tau pathol-
ogy are littered with uncleared microglial debris. Although not yet
shown, it would hardly come as a surprise to find out that the ability
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FIGURE 3 | Comparison of normal (ramified) and degenerating
(dystrophic) microglia using Iba1 immunostaining in human cerebral
cortex. (A) 22-year-old male non-demented subject reveals cells with
normal morphology; (B) 48-year-old female subject with Down syndrome
shows cells displaying obvious cytoplasmic fragmentation. Scale bar:
50µm.
of cytorrhectic microglia to produce sufficient amounts of neu-
rotrophic factors is much reduced. The possibility also exists that
dying microglial cells could elaborate toxic factors, which might
be a way to reconcile the dysfunction and neuroinflammation
ideas.
For quite some time now the presence of increased brain iron
and/or a disturbance in iron metabolism has been seen as a major
factor contributing directly to free radical mediated neuronal
degeneration (Jellinger et al., 1990; Dexter et al., 1991; Youdim
and Riederer, 1993; Lynch et al., 2000; Berg et al., 2001; Zecca et al.,
2004; Smith et al., 2010). Here again,microglial degeneration offers
an opportunity to deepen our understanding of the importance
of brain iron in the pathogenesis of neurodegenerative diseases.
As levels of brain iron increase with aging, perhaps due in part to
presence of microbleeds, the burden for resident microglial cells
in sequestering free iron through ferritin expression becomes pro-
gressively higher. At the same time the risk for microglia to develop
degenerative changes through iron-mediated oxidative stress is
heightened, thus resulting in an ever increasing number of dys-
trophic and dysfunctional microglial cells with impaired ability to
provide neuroprotection. Observations in humans showing that a
large proportion of ferritin-positive microglia are dystrophic and
that these dystrophic cells accumulate in advanced lesions (senile
plaques) substantiate this line of thinking (Kaneko et al., 1989;
Lopes et al., 2008; Xue and Streit, 2011).
As mentioned, there is an increasing number of recent stud-
ies that suggest significant involvement of microglia in synaptic
plasticity (Tremblay et al., 2011). If microglia are indeed the electri-
cians of the brain and important for maintaining synaptic integrity
of neuronal circuits (Graeber, 2010), then their deterioration in the
AD brain could certainly play a direct role in the loss of synapses
which represents a hallmark feature of the disease (DeKosky and
Scheff, 1990; Terry et al., 1991; Lassmann et al., 1993). Naturally, if
the dysfunction hypothesis is correct and microglial degeneration
contributes to neurodegeneration, the loss of synapses secondary
to neuronal degeneration would also fit into this scenario. Some
studies have suggested a role for microglia in synapse elimination
as well as in synaptogenesis during CNS development (Bessis et al.,
2007), and these functions are likely to be performed much more
effectively by young microglial cells in the developing brain than
by senescent ones in the aged CNS.
CONCLUSION
As the brain’s innate immune system one might be inclined to
think of microglia primarily as immunological defenders that fight
invading microorganisms. However, in so doing one underesti-
mates their importance as supportive and neuroprotective glial
cells essential for helping to maintain neuronal functioning in
the normal CNS and especially their crucial involvement in CNS
repair and regeneration during injury and disease. We believe that
microglial neuroprotection constitutes a most important aspect
of the cells’ biological significance because it defines a single com-
mon denominator that contributes to improved understanding
of CNS development, normal adult brain function, as well mech-
anisms of injury, disease, and repair. Specifically, with regard to
aging-related neurodegenerative diseases, which represent one of
the greatest challenges for biomedical science in this day and age,
we think that the concept of CNS immunosenescence has con-
siderable potential for advancing progress in terms of new and
improved approaches toward treatment and prevention.
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